Bio Screening Industry News

16/06/2005 - IDBS introduces the E-Workbook, an electronic laboratory notebook, which aims to provide a viable alternative in the way chemists, biologists and pharmacologists record, share and report all relevant experimental information.

Currently, the vast majority of scientific researchers still index their day-to-day results and observations in paper lab books. The problems of data mining and knowledge exploitation of such a system can result in inaccuracies, missing or incomplete information.. The E-Workbook, has been designed with the drug discovery scientist in mind, drawing on “real world” knowledge and using the experiences of R&D scientists to produce a flexible working tool.

This next generation electronic laboratory notebook (ELN) incorporates regulatory compliance, 21 CFR part 11, and IP protection, which are fundamental to the success of today’s drug companies.

“We are providing E-WorkBook as a core component of our integrated enterprise data management solution for drug discovery,” said Dr Paul Denny-Gouldson, IDBS product manager for E-Workbook.

“Practicality has to be the key word for any ELN and our starting point with E-Workbook was that such a system must fit into the R&D scientist’s existing routine and systems as seamlessly as possible,” he added.

The E-Workbook is applicable for all different chemistry disciplines and works with standard chemistry tools such as ISIS draw, ChemDraw, Accord, ChemAxxon and ChemIQ/Xtra as well as the open standard tools such as Microsoft Office.

The open standard component architecture allows the integration with other of IDBS’ products. For example, registering compounds in ActivityBase from the ELN is possible.

ActivityBase is a suite of discovery experiment management applications that enable scientists to capture, manage and use all of the data fuelling the drug discovery process, from structure registration, to screening, to dose response, to behavioural studies. A single, integrated discovery informatics framework brings together biological data and chemical information.

Data from different therapeutic and project areas can be organised in a consistent, user-friendly workspace that makes it easy to identify structure activity relationships and speed up decision-making processes.

ActivityBase integrates with Microsoft Excel and Microsoft Word and Oracle, the industry standard relational database application. ActivityBase’s built-in flexibility readily accommodates your existing project structures and workflow.

The E-Workbook is now available to purchase. For more information, visit IDBS’ website.

BIRMINGHAM, Ala., June 17 /PRNewswire/ — The National Institutes of Health (NIH) announced $88.9 million in grant awards to establish a collaborative research network that will use robotic high-throughput screening methods to identify small molecule probes as tools for new drug discovery. Southern Research was one of nine U.S. research organizations selected to participate in the NIH Roadmap Molecular Libraries initiative to support multidisciplinary medical research.

Southern Research, with an established track record of having discovered six of the FDA approved anti-cancer drugs on the market, will operate the Southern Research Molecular Libraries Screening Center (SRMLSC), receiving an estimated $11.6 million in NIH grant support during the three-year period. Gary A. Piazza, Ph.D., a pharmacologist and manager of Cell Biology and Immunology at Southern Research, will serve as the principal investigator for the SRMLSC project and will lead biological studies. Joseph A. Maddry, Ph.D., a chemist and director of Organic Chemistry, will lead the chemistry and informatics effort. Piazza and Maddry are both senior research scientists in the renowned Drug Discovery and Development Divisions at Southern Research.

“Now that the human genome has been sequenced, small molecules will provide valuable tools to probe the biological function of new genes at the cellular level,” said Piazza. “This is an exciting new opportunity that will escalate drug discovery by providing insight about how proteins can be pharmacologically controlled in disease processes.”

“The human genome initiative supplied us with the foundation of genes and proteins that are medically important,” said Maddry. “This screening effort is the next logical step, allowing us to identify small molecules that affect these proteins in certain specific ways. Then the chemists will use this information to design related compounds with more drug-like properties.”

Small molecules offer great potential to help scientists in their efforts to learn more about key biological pathways that are involved in human health and disease and should lead to safer and more effective drugs for the treatment and prevention of a range of disorders such as cancer and Alzheimer’s disease. The Molecular Libraries Screening Centers Network is being developed through the NIH Roadmap for medical research. Specifically, the network is part of the Roadmap’s “New Pathways to Discovery” initiative, which has set out to advance the understanding of biological systems and build a better “toolbox” for medical researchers in the 21st century.

“This tremendous collaborative effort will accelerate our understanding of biology and disease mechanisms,” said Elias A. Zerhouni, M.D., NIH Director. “More importantly, it will, for the first time, enable academic researchers to explore novel ideas and enable progress on a broad front against human disease.”

Data generated from the high-throughput assays conducted at the screening centers will be made available to researchers in both the public and private sectors through the PubChem database, created and managed by the National Library of Medicine at NIH.

The eight other institutions who received grants as part of the Molecular Libraries Screening Centers Network (MLSCN) include: Columbia University Medical Center, New York, NY; Emory University, Atlanta, Ga.; The Burnham Institute, La Jolla, Calif.; The Scripps Research Institute, La Jolla, Calif.; the University of New Mexico Albuquerque, Albuquerque, NM; University of Pennsylvania, Philadelphia, Pa.; the University of Pittsburgh, Pittsburgh, Pa.; and Vanderbilt University, Nashville, Tenn.

ABOUT SOUTHERN RESEARCH INSTITUTE

Alabama-based, full-service contract research organization Southern Research provides quality essential services in preclinical drug discovery and development for a wide range of diseases. With six FDA-approved drugs and another four in clinical trials, Southern Research continues to demonstrate research excellence and partnering value in the search for tomorrow’s breakthrough discoveries. Visit www.southernresearch.org or call 1-800-967-6774. Look for Southern Research in the Alabama Pavilion (Booth #1349) at the BIO 2005 Annual International Convention in Philadelphia, June 19-22, 2005.

ABOUT THE NIH ROADMAP FOR MEDICAL RESEARCH

The NIH Roadmap is a series of new initiatives designed to pursue major opportunities and gaps in biomedical research that no single NIH institute could tackle alone but which the agency as a whole can address to make the biggest impact possible on the progress of medical research and to catalyze changes that will serve to transform new scientific knowledge into tangible benefits for public health. Additional information about the NIH Roadmap can be found at its Web site, www.nihroadmap.nih.gov . For more information about NIH and its programs, visit www.nih.gov .

Although doctors and researchers have had a number of successes in the diagnosis and treatment of cancer, we need to stress cancer prevention.

Prevention is the key to reducing cancer, but only a small percent of the resources devoted to cancer are used to encourage prevention. For example, many sources give information on cancer screening and treatment, but scant information is available on how to avoid getting sick.

A case in point is prostate cancer. In Illinois, almost 10,000 new cases of prostate cancer are diagnosed each year. Many people diagnosed will have surgery, radiation and other procedures. Yet, a significant percentage of these cancers might be preventable - possibly by something as simple as taking a dietary supplement.

Prostate cancer is more common among African-Americans and men living in northern climates. There is a straightforward connection between these two groups that might help to prevent prostate cancer: vitamin D.

Vitamin D is a fat-soluble vitamin that helps deposit calcium in the bone. Interestingly, vitamin D needs sunlight to become activated. Increased melatonin in the skin of African-Americans reduces the activation of vitamin D. Those living in northern climates have less overall sun exposure (and vitamin D activation).

A recent study in the medical news journal Internal Medicine World Report concluded that higher blood levels of activated vitamin D were associated with a considerably reduced risk of prostate cancer. This data came from the Physicians Health Study, which tracked 1,082 physicians who developed and later died from prostate cancer and compared them to 1,701 other men of the same age.

What was discovered was that those with lower levels of vitamin D were at double the risk of developing prostate cancer and had three to four times the risk of contracting aggressive prostate cancer compared to the other men. Indeed, those with vitamin D levels above normal had a 45 percent reduction in the risk of ever developing prostate cancer. Men living in Asian countries, where the diet is rich in fish, have the highest levels of vitamin D and lowest levels of prostate cancer in the world.

Considering the thousands of dollars in medical costs and personal trauma resulting from prostate cancer, it is encouraging to think that up to 45 percent of new cases could be prevented for pennies a day.

We know that vitamin D affects cell growth and can cause cancer cell death. Recent research has demonstrated that vitamin D might act at the DNA level, promoting the production of natural anti- cancer compounds like tumor necrosis factor (TNF). Higher levels of serum vitamin D might promote higher levels of natural anti-cancer compounds like TNF. Lower vitamin D levels might do the opposite.

The recommended daily dose of vitamin D is 400 IU. Higher daily doses (possible as little as 800 IU/day) might be required for the most benefits. Although fish, fortified milk and egg yolk are sources of vitamin D, multivitamins and dietary supplements might be more convenient.

Billions have been spent in research, diagnosis and treatment of cancer. Hospitals and medical centers nationwide emphasize innovations and cutting edge therapies, but few stress prevention - and prevention is where we really need to be.

- Patrick B. Massey, M.D., Ph.D., is medical director for alternative and complementary medicine for Alexian Brothers Hospital Network. His Web site is www.alt-med.org.

Source: Daily Herald; Arlington Heights, Ill.

By wire services
Published June 17, 2005

Scripps Research Institute has been awarded a $10.4-million grant from the National Institutes of Health to establish a molecular screening center that will help translate basic biomedical discoveries more quickly into medical applications. Chemical compound development will take place at Scripps’ La Jolla, Calif., campus while high-throughput screening of those compounds to find promising molecules will be performed at Scripps Florida’s temporary labs in Jupiter. Scripps is one of 10 screening centers from the public and private sectors that will comprise the Molecular Libraries Screening Centers Network, an NIH project intended to accelerate drug discoveries. Scripps researchers will screen at least 100,000 compounds a year against 20 or more different disease targets. The project is expected to last three years and begins this month.

SAN DIEGO, Calif., June 17 (AScribe Newswire) — The Burnham Institute has been selected by the National Institutes of Health (NIH) as one of nine national centers for high-throughput chemical compound screening, known collectively as “The Molecular Libraries Screening Centers Network”, that will comprise the world’s largest collaborative network focused on drug discovery. Dr. John C. Reed, President and CEO of The Burnham Institute, will direct “The San Diego Chemical Library Screening Center” to be established with $11.9 M awarded over three years by the NIH.

As a member of this national screening network, the Burnham will have access to a library of 2 million compounds, which will be individually tested for medicinal properties using advanced robotic screening instrumentation. The screening center at the Burnham will perform screens of the 2 million compounds against at least 20 disease-targets per year, revealing specific compounds that interact with and inhibit disease-causing proteins.

“The selection of Burnham and our partner organizations to serve as one of the nine national centers for this exciting initiative validates our decision over five years go to build an innovative drug discovery infrastructure that empowers our scientists to go beyond basic discovery research and invent the new medicines of the future”, said Dr. Reed. “It is also a vote of confidence in the quality of our scientific team. Already, Burnham scientists have contributed in whole or in part to several medications now in use for preventing or treating stroke, heart attack, cancer, nerve degeneration, and Alzheimer’s disease. Armed with the new capabilities provided through the NIH grant, we will be poised to accelerate our efforts 100-fold.”

The Molecular Screening Centers Network is being developed as part of the NIH Roadmap Initiative for expediting medical discovery, implemented by NIH Director Elias A. Zerhouni, M.D. “This tremendous collaborative effort will accelerate our understanding of biology and disease mechanisms, said Dr. Zerhouni. “More importantly, it will, for the first time, enable academic researchers to explore novel ideas and enable progress on a broad front against human disease”.

Information generated by the screening centers will be made available to the public and private sectors through a database maintained by the National Library of Medicine at NIH.

The Burnham Institute’s component of the screening network will be staffed by a multi-disciplinary team of scientists, which includes experts in biology, chemistry, engineering, physics, and computer sciences. Promising compounds identified by robotic screening will be optimized for potency and safety using cutting-edge methods of structure-based drug design. The screening center employs and develops advanced instrumentation and methods for high-throughput automated microscopy, allowing for cell-based screens using high content imaging, as well as performing methods development in Nuclear Magnetic Resonance (NMR)-based drug design, 3D computational modeling, and combinatorial chemistry.

Design and implementation of screening assays, robotic chemical library screening, bioinformatics and data management will be undertaken at Burnham. Participants in the “San Diego Chemical Library Screening Center” from The Burnham Institute include Kristiina Vuori, M.D., Ph.D. (cell biology), Deputy Director of the Screening Center and Deputy Director of the Institute’s NCI Cancer Center; Jeffrey Price, Ph.D. (engineering), Associate Professor; Mark Mercola, Ph.D. (stem cell biology), Associate Professor; Steve Vasile, Ph.D. (high-throughput screening), Professor; Maurizio Pellecchia, Ph.D. (chemistry), Associate Professor; Adam Godzik, Ph.D. (computational biology), Professor and Director, Bioinformatics Program; Andrei Osterman, Ph.D. (computational biology), Assistant Professor; and Kutbuddin Doctor, Ph.D. (computational biology). The chemistry efforts to optimize drugs is performed at Burnham and two collaborating San Diego research organizations, the Torrey Pines Institute for Molecular Studies (TPIMS), led by Richard A. Houghten, Ph.D., President/CEO, and the Human Biomolecular Research Institute (HBRI), directed by John Cashman, Ph.D., President & CEO.

“This is a merger of immense synergistic talents,” said Dr. Houghten, “that will allow us to advance the discovery of new medicines at a pace heretofore unimaginable. We at TPIMS are very excited to be a part of this historic effort for San Diego and the nation.”

Projects underway at Burnham, TPIMS, and HBRI include design of drugs that selectively kill cancer cells, cytoprotective drugs for reducing cell loss during stroke, neurodegeneration, heart disease, and trauma, drugs that neutralize the anthrax toxin and other bacterial toxins, radioprotective drugs, drugs that suppress inflammation and autoimmunity for diseases including rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease, drugs for behavioral diseases including attention deficit disorder, substance abuse, schizophrenia, and bipolar disease, and drugs for pain management.

The Burnham Institute, founded in 1976, is an independent not-for- profit biomedical research institution dedicated to advancing the frontiers of scientific knowledge and providing the foundation for tomorrow’s medical therapies. The Institute is home to three major centers: the original Cancer Center, the Del E. Webb Neuroscience and Aging Center established in 1999, and the Infectious and Inflammatory Disease Center dedicated in 2004. Since 1981, the Institute’s Cancer Center has earned the prestigious designation as a Non-comprehensive Cancer Center by the National Cancer Institute. Discoveries by Burnham scientists have contributed to the development of new drugs for Alzheimer’s disease, heart disease and several forms of cancer. Today the Burnham Institute employs over 700, including more than 550 scientists. The majority of the Institute’s funding derives from federal sources, but private philanthropic support is essential to continuing bold and innovative research. For additional information about the Institute and ways to support the research efforts of the Institute, visit www.burnham.org .

BY JACK WONG

KUCHING: More minority groups are expected to contribute plant species known to have medicinal value to the Sarawak Biodiversity Centre’s bio-prospecting programme.

Those expected to do so in the next few months include the Bisayas from Limbang, Kayan-Kenyahs from Sungai Asap, Melanaus from the Mukah division and Ibans from Selangau and Betong.

State Planning and Resource Management Minister Datuk Awang Tengah Ali Hasan said the centre had met with leaders of these groups on taking part in its traditional knowledge documentation programme.

“The centre already has a collection of some 9,000 plant extracts in its natural product library from over 600 plant species from the local communities,” he told the state assembly during question time yesterday.

These species were contributed by the Bidayuhs, Penans, Kelabits, Lun Bawang and Malays from the various regions.

Awang Tengah said the centre’s two laboratories started carrying out extraction of plant samples and early-stage screening for bioactive compounds 16 months ago.

These facilities, he added, could enable research officers to conduct preliminary scr-eening for potential anti-cancer compounds.

He said five more laboratories, expected to be ready in three months’ time, would enhance the centre’s capabilities in the chemical analysis of plants for the development of various therapies, microbial prospecting for potential antibiotics and industrial enzymes, DNA sequencing of organisms and plant tissue culture and bioinformatics.

“Currently, five research officers are being trained by our Japanese partners (biotech company Nimura Genetic Solutions) in various techniques in microbial prospecting,” he added.

Awang Tengah said the state had to build up a critical mass of scientific expertise, to have access to research findings and good research partners to jumpstart its biotech initiative.

“When the new laboratories are fully commissioned and the research team adequately trained, the centre will be on track to bring in some discoveries,” he added.

Assistant Minister in the Chief Minister’s Department (human resources and training) Datin Fatimah Abdullah told the assembly more graduates in Sarawak were unemployed as they were choosy about jobs.

Statistics, she said, showed that unemployed graduates who were actively job-hunting rose from 3,393 in 2001 to 3,708 in 2002 and 4,744 in 2003, making up close to 13% of the total number of unemployed people in 2003.

Deputy Chief Minister Tan Sri Dr George Chan Hong Nam said the Sarawak Skills Development Centre had a nine-month training programme for unemployed graduates in food processing and packaging, plantation management and deep-sea fishing.

Malaysia Star - Petaling Jaya,Malaysia

One of the most important issues of discovery medicinal chemistry today is the continuing need for excellent synthetic chemists, feel Dr Ramaiah Muthyala and Dr Akella Venkateswarlu

Medicinal chemistry represents the design and discovery of new compounds that are suitable for use as drugs. The discovery of a new drug is not confined to include design and synthesis, but also the development of testing methods and procedures needed to establish how a substance operates in the body and its suitability for use as a drug. Drug discovery may also require fundamental research into the biological and chemical nature of the disease state.

Medicinal chemistry attempts to provide a framework for a variety of topics. In other words, a medicinal chemist has his/her own language—therapeutic index, hits, leads, SAR, QSAR, logP, receptors, ligands, pharmacophore, toxicophore, therapeutic window, pharmacokinetic and pharmacodynamics etc—which is foreign or less familiar, to most pure synthetic organic chemists.

In recent years, new scientific advancements in synthetic methodologies and novel technologies have revolutionised the practice of synthetic organic chemistry.

Drug design has received a big boost from disciplines such as combinatorial chemistry, automated synthesis and compound purification and identification. In addition, with the introduction of high-throughput screening, many targets are being assayed and many hits being evaluated simultaneously.

However, success in this arena still requires skilled medicinal chemists who make correct choices about which ‘hits’ are likely to play out as true ‘lead’ structures. These choices are often made with insights gleaned from interactions with computational chemists, structural biologists and a host of other disciplines. Even though the lead structure will have a long road ahead, it is expected that on the way it will meet a plethora of hurdles to survive to become a successful drug.

Those who are most proficient with computational tools have the advantage of delivering new drug candidates more quickly and at lower cost than their competitors. The systematic use of a wide range of computational tools facilitates and enhances the drug discovery process. Many tools are available. For example 2D or 3D library screening for lead compounds, predicting the properties of drug-like molecule, docking experiments, virtual screening etc. The synthetic chemists and medicinal chemists should be familiar with all these tools.

Full article

SAN DIEGO–(BUSINESS WIRE)–June 15, 2005–Novasite Pharmaceuticals Inc., a company focused on the discovery and development of allosteric modulators of G-protein coupled receptors (GPCRs), today announced that it has acquired PsyCheNomicS, Inc., a drug discovery company focused on diseases of the central nervous system (CNS). Financial terms of the transaction were not disclosed.

“The PsyCheNomicS acquisition provides Novasite with high-quality CNS drug leads, our area of therapeutic focus. Importantly, through this transaction we have also substantially augmented our management team with the appointment of Dr. James Hauske, a drug discovery and development veteran, whom we welcome as Executive Vice President of Drug Discovery,” commented Tim Harris, Ph.D., President and Chief Executive Officer of Novasite. “These new compound assets complement Novasite’s existing pipeline and our core structure-function analysis and single-cell screening technologies. Novasite’s business model is to apply our powerful discovery technologies to promising leads and rapidly advance them into clinical evaluation to create value for our stakeholders.”

“This is a great opportunity to add value to an organization with differentiating technology in GPCR drug discovery and excellent science, and it is a pleasure to join such a team,” said Jim Hauske.

James Hauske, Ph.D.

Dr. Hauske joins Novasite from PsyCheNomicS, the CNS drug discovery startup he founded. While at PsyCheNomicS, Dr. Hauske developed technology to identify small molecule drug candidates that bind to distinct sets of disease-relevant molecular targets including GPCRs. Jim held executive positions at Beyond Genomics, Sepracor, Arris (now part of Celera), and Pfizer. He has extensive experience in medicinal chemistry and preclinical development, including the discovery of GPCR active drugs. During his 25 years in the pharmaceutical industry he has taken eight new chemical entities into clinical development including candidates that have progressed through various phases of testing and commercialization.

About Novasite Pharmaceuticals

Novasite is a drug discovery and development company with a pipeline focused on diseases of the central nervous system and other areas of unmet medical need. Novasite’s pipeline is enhanced by its understanding of structure-function relationships and the discovery of allosteric modulators for validated G-protein coupled receptor (GPCR) targets. Allosteric modulators are compounds that affect GPCR function by binding at a site distinct from the natural ligand binding site and are believed to have a more effective mechanism of action than traditional therapeutics. Novasite’s technology base is comprised of a powerful receptor mutation-profiling methodology coupled with a proprietary single cell screening system that has been optimized to detect allosteric modulators.

NEW BRUNSWICK, N.J., June 15 /PRNewswire/ — WellGen, Inc., a biotechnology company using nutrigenomics to develop proprietary wellness products, announced today that it has renewed and expanded both its research contract and licensing agreement with Rutgers, The State University of New Jersey. The license agreement was expanded to include several new bioactive compounds and novel technologies including numerous pending patent applications in the area of nutrigenomics, such as anti-inflammatory compounds and an innovative technology for in vitro validation of anti-inflammatory compounds.

WellGen’s products include an anti-arthritis compound and an anti-colon cancer compound, which will complete human clinical trials this year. WellGen has also developed preclinical compounds in the areas of anti-obesity, exercise recovery and exercise performance.

“The expansion of our relationship with Rutgers University enhances our ongoing collaboration in nutrigenomics which will pave the way for exciting new discoveries, while greatly expanding the WellGen product pipeline,” said David A. Evans, geneticist and chief executive officer of WellGen. “We worked hard to develop a relationship with Rutgers that inspires true innovation. The decision of Rutgers to extend and expand our agreements directly reflects our progress as an independent company.”

The WellGen discovery platform is based on nutrigenomics. Nutrigenomics focuses on the role of nutrients and dietary ingredients on gene expression in the human body. Some chemicals found in commonly consumed foods are dietary signals that influence gene and protein expression and, subsequently, metabolite production. Nutrigenomics seeks to examine and exploit the way nutrition influences human disease. It is possible to identify foods and food ingredients that alter expression of genes associated with onset or proliferation of various diseases and conditions. WellGen believes that alteration of expression of disease-causing genes will aid in the prevention or treatment of human diseases.

WellGen’s core intellectual property, licensed from Rutgers, was developed by the nationally recognized Rutgers Food Science department in conjunction with the Rutgers Chemistry department, School of Pharmacy, and the University of Medicine and Dentistry of New Jersey. The patented gene screening technology was the foundation upon which WellGen was started. Along with the screening technology, WellGen gained exclusive access to bioactive compounds found to positively regulate expression of specific genes associated with disease. WellGen intends to continue funding research at Rutgers University for the ongoing discovery and pre-clinical validation of new bioactive compounds and technologies and to complete extensive safety and efficacy tests on their products, culminating in human clinical trials.

“We are excited about the progress at WellGen. We hope that our joint programs in nutrigenomics will result in several new technologies and products that will help treat or prevent important human diseases,” said Dr. Michael Breton, Rutgers’ associate vice president for research and sponsored programs. Rutgers has a small equity stake in WellGen.

About WellGen

WellGen is the first biotechnology company using nutrigenomics to discover and develop proprietary products that treat and prevent disease. Please visit our website at www.wellgen.com for more information about the company.

Combinatorial chemistry has evolved from the concept of producing massive numbers of compounds to smaller, more focused libraries. Now is a good time to review the current thinking and state-of-the art in Diversity Oriented Synthesis so, Select Conferences are pleased to announce their first conference focused in this area. To be held 22-23 Sept 2005 in Waltham, near Boston, MA, this will provide a major forum to present cutting edge work within this dynamic field and an un-missable event for those wishing to keep abreast of new developments.

Agenda sessions include:

Novel Synthetic Methodologies
- chaired by Dr. Gerard Rosse, Sanofi-aventis
High Throughput Strategies
- chaired by Dr. Thierry Masquelin, Lilly Corporate Center
Design and Synthesis Approaches
- chaired by Dr. Joseph M. Salvino, Cephalon, Inc.
Advances in Library Purification
- chaired by Dr. John J. Isbell, Novartis Research Foundation.

Keynote Speaker

Dr. John A. Porco, Jr., Department of Chemistry, University of Boston will deliver the keynote lecture entitled “Approaches to the Discovery of Novel Chemical Reactions and Chemotypes”.

For the full downloadable agenda please visit www.DOSconference.com

Selected media partnerships are available for this event.

About Select Conferences

www.SelectConferences.com

The Select Conferences division of Select Biosciences Ltd. is focused on organizing specialist biomedical meetings. Experts from both academia and commerce are invited to present timely information from current research through to commercial implementation of new technologies. These events also provide a unique networking facility and the opportunity to reach a highly targeted scientific audience.